Celebrate Father’s Day with $100 off Galleri! Must be 50+ and request online to be eligible.

Learn More

Now you can screen for multiple cancers with a simple blood draw1,2

Introducing Galleri®, the first-of-its-kind multi-cancer early detection test that looks for many cancers not commonly screened for today.




I am interested in learning more about the Galleri test


Healthcare Providers

Healthcare Providers

I am a healthcare provider interested in offering the Galleri test to my patients




I represent an employer interested in offering the Galleri test to my organization’s employees


Health Systems

Health Systems

I represent a health system interested in making the Galleri test available to my patient population

What is the Galleri test?

Galleri is a multi-cancer early detection (MCED) test that looks for a signal shared across more than 50 types of cancer through a simple blood draw. Many of these cancers are not commonly screened for today and otherwise may go unnoticed before symptoms appear.

Who is it for?

The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older. 

  • Only your healthcare provider can determine if Galleri is right for you. 
  • Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Sign up for more information about the Galleri test

Why is early detection important?


Around 70% of new cancer cases and cancer-related deaths are due to cancers with no recommended screening.3


Only 5 types of cancers have a recommended screening test — breast, colorectal, lung, cervical, and prostate.4,5


When cancer is detected in its early stages, before it has spread, the overall 5‑year survival rate is 4 times higher than when diagnosed in later stages.6,7

We collaborated with leading cancer institutes to study the Galleri test, including

Memorial Sloan Kettering
Knight Cancer Institute
Cleveland Clinic
Dana Farber
Cancer Research UK
JH Medicine

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected” does not rule out cancer. A test result of Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory / Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

Have more questions?

Please answer the following questions to fill in the appropriate form. 

You can also contact us at (833) 694‑2553 or use the chat feature on the page for additional help.

What describes you best?
What are you looking for?
Fill in the form

Celebrate Father’s Day with $100 off Galleri!

This offer applies to Galleri tests requested online through our independent telemedicine provider. You must be 50 years or older to take advantage of the offer, eligibility will be assessed at the time of your test request.

The discount only applies to full-priced, self-pay tests priced at $949 and will expire on June 18, 2023. Galleri is not currently covered by health care insurance.

Use Galleri Key FATHER23” when you request the test.

Limited time offer valid only for Galleri test orders placed June 5, 2023 12:00am PST through June 18, 2023 11:59pm PST. Valid only for Galleri test orders requested online and approved by contracted independent telemedicine healthcare provider. Offer does not confirm your eligibility for the Galleri test. Valid only for one-time use on domestic U.S. Galleri test orders only. Offer valid only for discount off of list price Galleri test orders ($949) and cannot be combined or used with any other discount, promotion, special pricing, or payment plan. Cannot be used to request a credit on a test order placed prior to the offer period. Cannot be posted online or on any other publicly available forum. GRAIL reserves the right to change terms and conditions, substitute offer of equal or greater value, and end offer at any time without notice. You must create an account to redeem this offer and enter the code at the “Introduction” stage, where prompted.

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167 – 1177. doi: 10.1016/j.annonc.2021.05.806.
  2. The Galleri test does not detect all cancers, nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to routine screening tests your healthcare provider recommends.
  3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database Incidence — SEER Research Limited-Field Data, 21 Registries, Nov 2020 Sub (2000−2018) — Linked To County Attributes ‑Time Dependent (1990−2018) Income/​Rurality, 1969 – 2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission.